Möchten Sie immer auf dem neuesten Stand bleiben?

CONNECTA Therapeutics initiates Phase IIa trial advancing treatments for rare CNS disorders, strengthening its clinical pipeline and development strategy.

Press release – No. 13 / 2026  New data from Phase 2 ZUPREME-1 trial at the American Diabetes Association 2026 Scientific Sessions further support potential of petrelintide to redefine the weight...

BPM31510 is a first-in-class therapeutic targeting tumor metabolism to re-program mitochondrial microenvironment in Warburg-avid tumorsBoth safety profile and efficacy data to be highlighted in...

Insiders are buying shares of $NTHI, $RIVN, $SRAD, $NWBI, and $FGBI

STORM Therapeutics announces a $56 million Series C financing to support the advancement of STC-15 in a Phase 2 study.

The United Laboratories International Holdings Limited and Novo Nordisk today announced topline results from a Chinese phase 2 trial of UBT251

Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Gastroesophageal (GE) Junction Carcinomas - Global Clinical Trials Review, 2025" clinical trials has been added to ResearchAndMarkets.com's...

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma focused on mitochondrial biology and protein homeostasis, today announced it has won...

Dublin, Nov. 05, 2025 (GLOBE NEWSWIRE) -- The "Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD or NAFLD) - Global Clinical Trials Review, 2025" clinical trials has been added to ...

BPGbio has completed phase 2b enrollment in late August this year for treatment of GBM with BPM31510Data further validate the MOA of BPM31510’s direct targeting of mitochondrial redox machinery to...